Related Experiment Video

Updated: Mar 6, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

SBRT for oligoprogressive oncogene addicted NSCLC

L Basler1, S G C Kroeze1, M Guckenberger1

  • 1Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, CH 8091 Zurich, Switzerland.

Lung Cancer (Amsterdam, Netherlands)
|March 14, 2017
PubMed

Insights

Lung cancer patients with EGFR or ALK mutations can develop resistance to targeted therapies. Treating limited oligoprogressive disease (OPD) with local therapies like SBRT may help overcome resistance and prolong survival.

Area of Science:

  • Oncology
  • Medical Physics
  • Genetics

Background:

  • Lung cancer, particularly lung adenocarcinoma, has poor outcomes despite advances.
  • Targeted therapies like tyrosine kinase inhibitors (TKIs) show initial efficacy in EGFR/ALK-mutated NSCLC but resistance develops.
  • Oligoprogressive disease (OPD) is a specific pattern of progression in a subset of patients on TKI therapy.

Purpose of the Study:

  • To review the biological mechanisms of TKI resistance in lung cancer.
  • To explore systemic and local treatment strategies for TKI-resistant lung cancer, focusing on OPD.
  • To discuss challenges in defining OPD and highlight ongoing clinical trials.

Main Methods:

  • Literature review of TKI resistance mechanisms in EGFR/ALK-mutated NSCLC.
  • Analysis of retrospective data on local treatments for oligoprogressive disease.
  • Discussion of SBRT, surgery, and other local modalities.
  • Review of diagnostic criteria and clinical trial designs for OPD.

Main Results:

  • TKI therapy offers superior outcomes compared to chemotherapy for EGFR/ALK-mutated lung cancer.
  • Resistance to TKIs is a significant clinical challenge, occurring in most patients.
  • Aggressive local treatment of oligoprogressive lesions may eradicate resistant clones and allow continued TKI therapy.
  • Stereotactic body radiotherapy (SBRT) is a promising local treatment option for OPD.

Conclusions:

  • Targeted therapies have revolutionized lung adenocarcinoma treatment but resistance remains a hurdle.
  • Identifying and treating oligoprogressive disease with local therapies, particularly SBRT, can potentially extend TKI treatment and improve patient survival.
  • Further research and standardized definitions are needed to optimize the management of oligoprogressive disease in NSCLC.
Keywords:
EGFR mutationOligoprogressive disease (OPD)Oncogene addicted lung cancerResistance to targeted therapyStereotactic body radiotherapy (SBRT)Tyrosine kinase inhibitors

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K